Back to results
US 2022/0023627 A1Published application
Methods for assessing efficacy of renal neuromodulation and associated systems and devices
AssigneeMedtronic Ardian Luxembourg S.a.r.l.
InventorsCarol Sullivan, Stefan Tunev
Life of this patent
Estimating the term…
Abstract
Provided herein are methods, devices and compositions for assessing neuromodulation efficacy based on changes in the level of one or more biomarkers in plasma or urine collected from a human subject following a renal neuromodulation procedure.
Claims18
1-42. (canceled)
A method of assessing efficacy of a renal neuromodulation procedure in a human subject, the methods comprising:
- determining a post-neuromodulation level of one or more biomarkers following the renal neuromodulation procedure, wherein the level of the one or more biomarkers directly or indirectly correlate with sympathetic nervous activity in the human subject;
- and
- comparing the post-neuromodulation level to a pre-determined level or range of levels for the one or more biomarkers;
- classifying the renal neuromodulation procedure as at least partially successful based on the comparison, wherein one or more of the biomarkers are selected from the group consisting of normetanephrine, vanillylmandelic acid, metanephrine, homovanillic acid, albumin, and microalbuminuria.
1 more element
Dependencies are inferred from the claim text.